FDA warned Delta Kozmetik that its OTC drug products were adulterated due to CGMP violations.
What happened
FDA inspected the Delta Kozmetik drug manufacturing facility in Tuzla, Istanbul, from September 12 to September 16, 2022. The inspection found that the firm did not adequately test incoming components or qualify suppliers, did not validate manufacturing processes or qualify equipment, and lacked an adequate stability program. FDA said the firm’s October 7, 2022 response was inadequate and placed the firm on Import Alert 66-40 on January 11, 2023; it had been placed on Import Alert 66-78 on May 17, 2021, due to violative sampling results.
What FDA found
The firm did not test each incoming component for identity and conformity with specifications before use, and it did not validate its suppliers’ test analyses.
21 CFR 211.84(d)(1) and 211.84(d)(2)The firm lacked adequate written production and process control procedures and had not validated its manufacturing processes or qualified its equipment.
21 CFR 211.100(a)The firm did not establish or follow an adequate stability testing program to support storage conditions and expiration dates.
21 CFR 211.166(a)
What FDA wants
FDA tells the company to correct the violations promptly and respond in writing within 15 working days with what it has done and a schedule for any remaining actions. FDA also recommends engaging a qualified CGMP consultant.
Who should pay attention
- U.S. importers and distributors of Delta Kozmetik OTC drugs
- companies buying OTC drug products made by this Turkish manufacturer
- supplier quality teams that rely on component certificates of analysis
This is a summary. Read the original letter on fda.gov.